Table 1.
Baseline demographics of microbiologically evaluable patients with monomicrobial Staphylococcus aureus infection with vancomycin minimum inhibitory concentration ≥ 1.0 µg/mL
| Characteristic | Telavancin (n = 89) | Vancomycin (n = 105) |
|---|---|---|
| Age (years) | ||
| Mean (SD) | 61.7 (18.6) | 67.0 (15.4) |
| Median (IQR) | 67.0 (50.0, 75.0) | 72.0 (60.0, 77.0) |
| Age distribution, n (%) | ||
| < 65 years | 40 (44.9) | 37 (35.2) |
| ≥ 65 years | 49 (55.1) | 68 (64.8) |
| Sex, n (%) | ||
| Male | 47 (52.8) | 61 (58.1) |
| Female | 42 (47.2) | 44 (41.9) |
| Ethnicity, n (%) | ||
| Hispanic or latino | 20 (22.5) | 21 (20.0) |
| Not hispanic or latino | 69 (77.5) | 84 (80.0) |
| Race, n (%) | ||
| American Indian or Alaska Native | 5 (5.6) | 3 (2.9) |
| Asian | 17 (19.1) | 20 (19.0) |
| Black or African American | 3 (3.4) | 4 (3.8) |
| White | 64 (71.9) | 78 (74.3) |
| BMI (kg/m2) | ||
| Mean (SD) | 26.2 (5.84) | 25.5 (6.03) |
| Median (IQR) | 25.4 (22.2, 29.1) | 23.8 (21.6, 28.3) |
| APACHE II Score (mean, SD) | ||
| Mean (SD) | 15.2 (6.09) | 15.5 (6.95) |
| Median (IQR) | 15.0 (11.0, 19.0) | 14.0 (11.0, 20.0) |
| CrCl (mL/min) | ||
| Mean (SD) | 89.7 (62.2) | 76.0 (57.4) |
| Median (IQR) | 68.5 (43.0, 118.5) | 63.6 (40.7, 91.7) |
| VAP, n (%) | ||
| Yes | 26 (29.2) | 21 (20.0) |
| No | 63 (70.8) | 84 (80.0) |
| MRSA, n (%) | ||
| Yes | 61 (68.5) | 88 (83.8) |
| No | 28 (31.5) | 17 (16.2) |
| MSSA, n (%) | ||
| Yes | 28 (31.5) | 17 (16.2) |
| No | 61 (68.5) | 88 (83.8) |
| Common comorbidities (≥ 20%), n (%) | ||
| Hypertension | 55 (61.8) | 67 (63.8) |
| Anemia | 39 (43.8) | 34 (32.4) |
| Diabetes mellitus | 35 (39.3) | 34 (32.4) |
| Atrial fibrillation | 22 (24.7) | 25 (23.8) |
| Cardiac failure, congestive | 22 (24.7) | 14 (13.3) |
| Chronic obstructive airways disease | 21 (23.6) | 31 (29.5) |
| Renal comorbidities | ||
| Renal failure, acute | 9 (10.1) | 12 (11.4) |
| Renal failure, chronic | 9 (10.1) | 9 (8.6) |
| Renal insufficiency | 4 (4.5) | 5 (4.8) |
| Renal impairment | 1 (1.1) | 0 |
| Blood creatinine increased | 1 (1.1) | 0 |
As treatment allocation was randomized, no statistical comparison of baseline characteristics was performed
APACHE II Acute Physiology and Chronic Health Evaluation II, BMI body mass index, CrCl creatinine clearance, IQR interquartile range, MRSA methicillin-resistant Staphylococcus aureus, MSSA methicillin-sensitive Staphylococcus aureus, SD standard deviation, VAP ventilator-acquired pneumonia